Medtronic's Renal Denervation Business Outlook Remains Positive Amid Mixed Quantitative Signals

June 2026,Medtronic(MDT) Due to market attention on its cardiac ablation, diabetes care, and hypertension treatment strategies, as well as the progress of its FDA-approved Symplicity Spyral renal denervation system, there is widespread focus. However, current interpretations of its short-term profitability prospects are divided, with some quantitative ratings turning cautious.

Key data points include: The Symplicity Spyral renal denervation ablation system has secured Medicare reimbursement coverage, with current annualized sales reaching $100 million; seven fair value estimates from the Simply Wall St community cluster in the range of $83.9 billion to $98.0 billion, suggesting that the potential value of the relevant stock could be up to 22% higher than its current price.

Medtronic’s core investment thesis currently rests on achieving compound growth in cash flow through its medical device business. The recent acquisition of Scientia Vascular represents a gradual enhancement of its neurovascular interventional access capabilities and does not constitute a significant fundamental transformation. Market focus is currently on short-term earnings risks, primarily concerning the adoption pace of renal denervation procedures and expected margin expansion risks.

Translated content is provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article is generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; relevant information shall be subject to actual announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Editor: Xiaolang Express